Public Citizen seeks Ortho Evra ban

Share this article:
Ortho-McNeil/Janssen said a Public Citizen petition to the FDA calling for removal of the Ortho Evra contraceptive patch from the market for safety reasons “presents no new information or scientific evidence showing that Ortho Evra is unsafe, ineffective or unnecessary” and should be denied. 

Public Citizen claimed in its petition last May that the patch exposes women to dangerous estrogen levels. The company's response, filed in October, said the allegations are contradicted by existing medical evidence. 

The company also said Public Citizen is ignoring the interactions between the FDA and Ortho-McNeil/Janssen on the product and the labeling contents that have been put in place since Evra's 2001 approval. 

“In particular,” the response said, “Public Citizen does not address revised labeling that discusses the difference in estrogen delivery between Ortho Evra and oral contraceptives. Moreover, Public Citizen's allegations of a greater risk of adverse events for Ortho Evra are predicated on unproven assumptions arising from Public Citizen's interpretation of pharmacokinetic data.”

Public Citizen's petition asked for a six-month transition period during which the contraceptive would be available for refill prescriptions to allow women time to meet with their healthcare providers and determine a safer alternative contraceptive method.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?